Drug Trial Radar · NCT07588906
To Compare the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability Between SHR-3167 Injection and Glargine Insulin in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Feb 26, 2024
Primary completion
Jul 12, 2024
Study completion Jul 23, 2024
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the pharmacodynamic profile of a single subcutaneous dose of SHR-3167 injection versus insulin glargine U100 in healthy subjects.
Conditions
- Healthy Subjects
Interventions
SHR-3167 injection;glargine insulinDrug
Drug: SHR-3167 injection Participants will receive a single subcutaneous (s.c.) injections of SHR-3167 injection Drug: glargine insulin Participants will receive a single subcutaneous (s.c.) injections of glargine insulin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Glucose infusion rate (GIR) - area under the curve (AUC)Time frame: Glargine period: 0-24hour ; SHR-3167 period: 0-226hour
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bishan Hospital of Chongqing
Chongqing, Chongqing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.